SCHEMBL23923863

SCHEMBL23923863

O=C(O)N1C[C@H](O)[C@H](c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.49
SLC18A3 Q16572 1/20 0.44
HTT P42858 1/20 0.42
KDM1A O60341 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
HDAC4 P56524 1/20 0.40
TLR2 O60603 1/20 0.39
TLR1 Q15399 1/20 0.39
CCR5 P51681 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
RORC P51449 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6127038 1.00 MYC (0.49) MYCSLC18A3HTTKDM1ASMN1; SMN2
SCHEMBL6127033 1.00 MYC (0.49) MYCSLC18A3HTTKDM1ASMN1; SMN2
SCHEMBL6042250 0.84 SLC18A3 (0.55) SLC18A3HTTKDM1ASMN1; SMN2NPC1
SCHEMBL2148749 0.84 TLR2 (0.41) MYCSLC18A3KDM1ANPC1RAB9A
SCHEMBL2241225 0.84 SLC18A3 (0.55) SLC18A3HTTKDM1ASMN1; SMN2NPC1
SCHEMBL5198510 0.84 SLC18A3 (0.47) SLC18A3HTTKDM1ASMN1; SMN2NPC1
SCHEMBL17514137 0.84 CYP1A2 (0.43) SMN1; SMN2NPC1TP53RAB9ATLR2
SCHEMBL5198776 0.84 SLC18A3 (0.47) SLC18A3HTTKDM1ASMN1; SMN2NPC1
SCHEMBL2241229 0.84 SLC18A3 (0.55) SLC18A3HTTKDM1ASMN1; SMN2NPC1
SCHEMBL5200597 0.84 SLC18A3 (0.47) SLC18A3HTTKDM1ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 MYC 467/4885SLC18A3 2603/4885HTT 1219/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 MYC 467/4885SLC18A3 2603/4885HTT 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.